Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
201
-
202
-
203
-
204
-
205
-
206
-
207
-
208
-
209
-
210
-
211
-
212
Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation.
Published 2013“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
-
213
-
214
-
215
-
216
OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts.
Published 2019“…However, co-treatment of OCA with Gemcitabine or Cisplatin resulted in a tumor volume significantly lower compared to Gemcitabine or Cisplatin alone (p < 0.05). Means ± SE of N = 5 for each group. * p < 0.05 vs controls, <sup>&</sup> p < 0.05 vs OCA, <sup>¤</sup> p < 0.05 vs Cisplatin alone, <sup>§</sup> p < 0.05 vs Gemcitabine alone. …”
-
217
-
218
-
219
Inclusion of TPP side chains result in decreased melanoma cell mitochondria membrane potential, oxygen consumption, and increased DHE oxidation.
Published 2020“…<p>(A) A375 melanoma cells were treated with 0.5 μM, 1.0 μM, or 2.0 μM 5-, 10-, or 16-TPP for 1 h and analyzed for mitochondria membrane potential by the JC-1 method (* significant relative to control; p<0.05; n = 2 from 2 separate experiments; N = 4). …”
-
220